Filing Flows › Emmaus Life Sciences (EMMA) › Q4 2024
Emmaus Life Sciences (EMMA) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Apr 14, 2025
Emmaus Life Sciences (EMMA) reported revenue of $3.3M for the fourth quarter 2024 (Q4 2024), -53% from a year earlier and -40% from the quarter before. Operating margin was -16.9%, net loss $1.7M (53.1% of revenue).
Emmaus Life Sciences, Q4 2024: revenue $3.3M (-53% year over year), operating margin -16.9%, net loss $1.7M, operating cash flow $343K. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.3M | -40% | -53% |
| Operating profit | −$557K | — | — |
| Net earnings | −$1.7M | — | — |
| Operating cash flow | $343K | +132% | -67% |
| Free cash flow | $337K | +126% | -67% |
What changed
Revenue was $3.3M in Q4 2024, down 53% year over year and down 40% from the previous quarter. Endari US was the largest line at 88% of revenue.
Gross margin was 90.6%, down 6.7 points from a year earlier. Operating costs exceeded revenue by $557K, an operating margin of -16.9%. Operating expenses fell 36% while revenue fell 53%. The quarter ended with a net loss of $1.7M, after a profit of $1.8M the previous quarter. Net interest and other expense of $1.2M was the main reason.
Operating cash flow was $343K (down 67% year over year). Non-cash charges added back $5K of depreciation and $29K of share-based compensation. Working capital and other items added $2.1M. Capital expenditures of $6K left free cash flow of $337K.
Questions
What was Emmaus Life Sciences' revenue in the fourth quarter 2024?
Emmaus Life Sciences (EMMA) reported revenue of $3.3M for the fourth quarter 2024 (Q4 2024), -53% from a year earlier and -40% from the quarter before.
Was Emmaus Life Sciences profitable in the fourth quarter 2024?
Operating loss was $557K (-16.9% of revenue) and net loss $1.7M.